Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at UCLA
Dates
study started
estimated completion
Principal Investigator
by Michelle Craske (ucla)

Description

Summary

Specific phobias and other anxiety disorders represent a major mental health problem, and present a significant challenge to researchers because effective treatment usually involves repeated exposure to feared stimuli, and the high levels of associated distress can lead to termination of treatment. Recent advances in computational functional magnetic resonance imaging (fMRI) provide a method by which individuals may be unconsciously exposed to fearful stimuli, leading to effective fear reduction while eliminating a primary cause of attrition. The objective of the current study is to use the novel approach of neuro-reinforcement based on decoded fMRI information to reduce fear responses to fearful stimuli (e.g., spiders, heights) in individuals with phobias, directly and unconsciously in the brain, without repeatedly exposing participants to their feared stimuli. Participants will be randomized into one of three groups of varying neuro-reinforcement sessions (1, 3, or 5). They will complete tests of subjective fear and directed attention while being scanned by fMRI to measure engagement of amygdala activity to fearful stimuli as well as measured through other indicators of fear such as skin conductance response.

Details

Anxiety disorders, the most common group of mental disorders in the United States, represent a major mental health problem. Phobias, in which fear and anxiety are triggered by a specific stimulus or situation, are the largest category of anxiety disorders and affect 5 - 12% of the world's population. Exposure-based therapies are effective in reducing symptoms, but their effectiveness depends on the individual's capacity or willingness to consciously confront their feared object. The associated distress can be so extreme that it prevents patients from seeking treatment, and contributes to attrition from exposure once treatment begins. As a result, there is an unmet need for treatment that minimizes attrition and subjective patient discomfort. The current study uses a novel technique of neuro-reinforcement based on decoded fMRI information to reduce fear responses to fearful stimuli directly and unconsciously without repeatedly exposing participants to those stimuli. The goals are to (1) confirm that our method decreases amygdala reactivity to images of phobic stimuli as well as (2) determine dosage-response optimization.

Keywords

Phobia unconscious fear extinction anxiety disorders decoded neuro-reinforcement Phobic Disorders Unconscious Neuro-reinforcement

Eligibility

You can join if…

Open to people ages 18-65

  • Individual has normal or corrected to normal vision
  • Individual has normal or corrected to normal hearing
  • Individual is competent to understand informed consent

You CAN'T join if...

  • Individual is unable to fill in consent form correctly
  • Individual is unable to respond adequately to screening questions
  • Individual is unable to maintain focus or to sit during assessment
  • Individual has history of: neurological disease or defect (e.g., stroke, traumatic brain injury, schizophrenia or other psychological disorders, or seizures)
  • Individual has vision problems (including cataracts, amblyopia, or glaucoma)
  • Individual presents with: PTSD, Obsessive Compulsive Disorder, Substance Use Disorder, Current Major Depression, Bipolar Disorder, Psychosis, neurologic diagnoses or unstable serious medical conditions
  • Individual does not present with more than one object of specific phobia
  • Individual can touch the phobic object category during the pre¬treatment Behavioral Approach Test without presenting significant distress
  • Individual is currently prescribed psychotropic medication

Location

  • University of California, Los Angeles accepting new patients
    Los Angeles California 90095 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT03655262
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated